Incyte’s Q3 2018 revenue estimates
As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. The estimates for the third quarter of 2018 are as follows.
The product portfolio includes two products, Jakafi and Iclusig. The revenues for both these products are expected to see growth during the third quarter of 2018, following strong sales in US markets. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.
Incyte receives royalties for Jakafi from Novartis and for Olumiant from Eli Lilly (LLY). Novartis (NVS) holds the license for development and commercialization of Jakafi outside the US and markets the drug as Jakavi. The royalty revenues from Jakavi sales are expected to see growth during the quarter. Eli Lilly (LLY) commercializes Olumiant (baricitinib) worldwide, and Incyte receives royalties for the sales of Olumiant. The royalty revenues from sales of Olumiant are expected to see growth during the quarter.
Incyte has some collaborative research and license agreements with Novartis and Eli Lilly. The contract revenues are related to milestone payments for the development of drugs under these agreements. These revenues are not included in the estimates above.